Citable filing context

CAH filing events and research context

Server-rendered

CAH's research view summarizes recent SEC filing context, starting with mda_quarterly from Apr 30, 2026.

CAH filing events and research context
FiledItemContext
Apr 30, 2026mda_quarterlyCardinal Health’s revenue for the three months ended March 31, 2026, increased 11% to $60.9 billion, driven primarily by branded and specialty pharmaceutical sales. Non-GAAP operating earnings rose 18% to $956 million, while GAAP operating earnings declined 30% to $509 million, largely due to a $184 million pre-tax goodwill impairment charge for the Navista & ION reporting unit. Growth was supported by the generics program and the expansion of Management Service Organization (MSO) platforms, including the $1.9 billion acquisition of Solaris Health. While GLP-1 pharmaceutical demand increased revenue, it did not meaningfully contribute to segment profit. The Global Medical Products and Distribution (GMPD) segment was negatively impacted by approximately $200 million in IEEPA tariffs; although the Supreme Court ruled these unlawful, the refund process remains uncertain. Additional growth occurred in at-Home Solutions following the Advanced Diabetes Supply Group (ADS) acquisition and through OptiFreight Logistics. Key financial risks include the "Most-Favored Nation" prescription drug pricing executive order and $4.3 billion in remaining opioid litigation settlement accruals. To fund acquisitions, the company issued $1 billion in new long-term debt and deployed $1 billion for share repurchases during the first nine months of the fiscal year.
Feb 5, 2026mda_quarterlyCardinal Health reported revenue of $65.6 billion for the quarter ended December 31, 2025, a 19% increase driven by branded and specialty pharmaceutical growth. Non-GAAP operating earnings rose 38% to $877 million, bolstered by the acquisition of Advanced Diabetes Supply (ADS) and the expansion of Management Service Organization (MSO) platforms, including the $1.9 billion acquisition of Solaris Health. While GLP-1 pharmaceutical demand significantly increased revenue, it did not meaningfully contribute to segment profit. The company’s "Other" segment grew 34% through at-Home Solutions and OptiFreight Logistics, while the Global Medical Products and Distribution segment grew 3% via existing customer volume. Key financial risks include the "Most-Favored Nation" prescription drug pricing Executive Order and U.S. tariffs, which have increased sourcing costs and may disrupt supply chains. Additionally, the company maintains a $4.3 billion accrual for opioid litigation settlements with payments scheduled through 2038. To support recent acquisitions, Cardinal Health issued $1.0 billion in new long-term debt, while deploying $750 million toward share repurchases during the first half of fiscal 2026.
Oct 30, 2025mda_quarterlyRevenue for the first quarter of fiscal 2026 increased 22% to $64.0 billion, driven primarily by growth in branded and specialty pharmaceutical sales. Non-GAAP operating earnings rose 37% to $857 million, bolstered by the acquisition of Advanced Diabetes Supply and Management Service Organization (MSO) platforms, including GI Alliance, Urology America, and Integrated Oncology Network. While demand for GLP-1 pharmaceuticals significantly increased revenue, these products did not meaningfully contribute to segment profit. The company entered a definitive agreement to acquire Solaris Health, a urology MSO, for approximately $1.9 billion in cash and $500 million in common units, supported by $1.0 billion in new debt issuance. Key headwinds include U.S. tariffs increasing sourcing costs, potential price reductions from the “Delivering Most-Favored Nation Prescription Drug Pricing” Executive Order, and utilization risks associated with the One Big Beautiful Bill Act. The Global Medical Products and Distribution segment saw growth in Cardinal Health brand products. Financial obligations include $4.3 billion accrued for opioid litigation settlements, with $403 million paid during the quarter. Non-GAAP diluted EPS increased 36% to $2.55, partially offset by increased interest expense from recent debt financing.

Source: SEC EDGAR filing text and events; period Apr 30, 2026; filed Apr 30, 2026.

Continue research

Keep researching CAH

Follow same-sector companies and source explainers connected to the research view.

Browse Health Care

Related tickers

LLY
Lilly (Eli)
$1.02T
Health Care
Open company page →
JNJ
Johnson & Johnson
$558.88B
Health Care
Open company page →
ABBV
AbbVie
$393.91B
Health Care
Open company page →
UNH
UnitedHealth Group
$369.32B
Health Care
Open company page →
MRK
Merck & Co.
$295.00B
Health Care
Open company page →
AZN
ASTRAZENECA PLC
$281.75B
Health Care
Open company page →

Related explainers

Understanding 8-K filings

A factual guide to SEC Form 8-K current reports and the material company events they can disclose between quarterly filings.

Read explainer →
Reading a 10-Q

A factual guide to quarterly SEC Form 10-Q reports, how they differ from annual 10-K filings, and what readers can inspect first.

Read explainer →
S-1 and the IPO prospectus

A factual guide to Form S-1 registration statements and the disclosures companies provide before a public offering.

Read explainer →
Reading an SEC 10-K

A factual guide to the core 10-K sections investors use for company context: business description, risk factors, MD&A, financial statements, and segment disclosures.

Read explainer →